Is Texas Instruments Stock Overvalued?
Texas Instruments Incorporated (NASDAQ:TXN) is not having an easy time…
Sell
44
ADXN Quote, Financials, Valuation and Earnings
Last price:
$7.58
Seasonality move
:
33.6%
Day range:
$6.81 - $7.98
52-week range:
$6.81 - $27.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.51x
P/B ratio:
0.59x
Volume:
74K
Avg. volume:
25.1K
1-year change:
-32.75%
Market cap:
$7.8M
Revenue:
$1.8M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
ACIU
AC Immune SA
|
$821K | -$0.21 | -95.08% | -273.39% | $9.89 |
|
CRSP
CRISPR Therapeutics AG
|
$7.4M | -$1.18 | -96.15% | -0.36% | $83.50 |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$0.59 | -- | -551.43% | $78.00 |
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -33.3% | $10.46 |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics
|
$7.31 | $30.00 | $7.8M | -- | $0.00 | 0% | 13.51x |
|
ACIU
AC Immune SA
|
$2.70 | $9.89 | $267.1M | -- | $0.00 | 0% | -- |
|
CRSP
CRISPR Therapeutics AG
|
$42.04 | $83.50 | $3.6B | -- | $0.00 | 0% | -- |
|
MLTX
MoonLake Immunotherapeutics
|
$47.12 | $78.00 | $3B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$5.23 | $10.46 | $192.7M | -- | $0.00 | 0% | 25.40x |
|
NLSP
NLS Pharmaceutics
|
$1.98 | -- | $7.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADXN
Addex Therapeutics
|
-- | 3.160 | -- | 4.36x |
|
ACIU
AC Immune SA
|
-- | 5.710 | -- | 1.82x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 3.448 | -- | -- |
|
MLTX
MoonLake Immunotherapeutics
|
-- | 1.800 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 2.282 | -- | 14.08x |
|
NLSP
NLS Pharmaceutics
|
-- | 2.905 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$43.1M | -- | -- | -- | -$25.4M |
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
Addex Therapeutics vs. Competitors
-
Which has Higher Returns ADXN or ACIU?
AC Immune SA has a net margin of -2841.85% compared to Addex Therapeutics's net margin of 21.59%. Addex Therapeutics's return on equity of 91.08% beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics-- -$2.78 $13.1M ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About ADXN or ACIU?
Addex Therapeutics has a consensus price target of $30.00, signalling upside risk potential of 310.4%. On the other hand AC Immune SA has an analysts' consensus of $9.89 which suggests that it could grow by 266.32%. Given that Addex Therapeutics has higher upside potential than AC Immune SA, analysts believe Addex Therapeutics is more attractive than AC Immune SA.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics0 0 0 ACIUAC Immune SA3 0 0 -
Is ADXN or ACIU More Risky?
Addex Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.294, suggesting its more volatile than the S&P 500 by 29.428%.
-
Which is a Better Dividend Stock ADXN or ACIU?
Addex Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or ACIU?
Addex Therapeutics quarterly revenues are $62.3K, which are smaller than AC Immune SA quarterly revenues of $29.5M. Addex Therapeutics's net income of -$1.8M is lower than AC Immune SA's net income of $6.4M. Notably, Addex Therapeutics's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics is 13.51x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics13.51x -- $62.3K -$1.8M ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns ADXN or CRSP?
CRISPR Therapeutics AG has a net margin of -2841.85% compared to Addex Therapeutics's net margin of --. Addex Therapeutics's return on equity of 91.08% beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics-- -$2.78 $13.1M CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About ADXN or CRSP?
Addex Therapeutics has a consensus price target of $30.00, signalling upside risk potential of 310.4%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.50 which suggests that it could grow by 98.62%. Given that Addex Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Addex Therapeutics is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics0 0 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is ADXN or CRSP More Risky?
Addex Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.
-
Which is a Better Dividend Stock ADXN or CRSP?
Addex Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or CRSP?
Addex Therapeutics quarterly revenues are $62.3K, which are larger than CRISPR Therapeutics AG quarterly revenues of --. Addex Therapeutics's net income of -$1.8M is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Addex Therapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics is 13.51x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics13.51x -- $62.3K -$1.8M CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns ADXN or MLTX?
MoonLake Immunotherapeutics has a net margin of -2841.85% compared to Addex Therapeutics's net margin of --. Addex Therapeutics's return on equity of 91.08% beat MoonLake Immunotherapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics-- -$2.78 $13.1M MLTXMoonLake Immunotherapeutics-- -$0.56 -- -
What do Analysts Say About ADXN or MLTX?
Addex Therapeutics has a consensus price target of $30.00, signalling upside risk potential of 310.4%. On the other hand MoonLake Immunotherapeutics has an analysts' consensus of $78.00 which suggests that it could grow by 65.54%. Given that Addex Therapeutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe Addex Therapeutics is more attractive than MoonLake Immunotherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics0 0 0 MLTXMoonLake Immunotherapeutics11 1 0 -
Is ADXN or MLTX More Risky?
Addex Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MoonLake Immunotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADXN or MLTX?
Addex Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MoonLake Immunotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics pays -- of its earnings as a dividend. MoonLake Immunotherapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or MLTX?
Addex Therapeutics quarterly revenues are $62.3K, which are larger than MoonLake Immunotherapeutics quarterly revenues of --. Addex Therapeutics's net income of -$1.8M is higher than MoonLake Immunotherapeutics's net income of -$35.4M. Notably, Addex Therapeutics's price-to-earnings ratio is -- while MoonLake Immunotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics is 13.51x versus -- for MoonLake Immunotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics13.51x -- $62.3K -$1.8M MLTXMoonLake Immunotherapeutics-- -- -- -$35.4M
-
Which has Higher Returns ADXN or MOLN?
Molecular Partners AG has a net margin of -2841.85% compared to Addex Therapeutics's net margin of -2408.81%. Addex Therapeutics's return on equity of 91.08% beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics-- -$2.78 $13.1M MOLNMolecular Partners AG-- -$0.57 $165M -
What do Analysts Say About ADXN or MOLN?
Addex Therapeutics has a consensus price target of $30.00, signalling upside risk potential of 310.4%. On the other hand Molecular Partners AG has an analysts' consensus of $10.46 which suggests that it could grow by 100.03%. Given that Addex Therapeutics has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics0 0 0 MOLNMolecular Partners AG2 1 0 -
Is ADXN or MOLN More Risky?
Addex Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADXN or MOLN?
Addex Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or MOLN?
Addex Therapeutics quarterly revenues are $62.3K, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. Addex Therapeutics's net income of -$1.8M is higher than Molecular Partners AG's net income of -$19M. Notably, Addex Therapeutics's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics is 13.51x versus 25.40x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics13.51x -- $62.3K -$1.8M MOLNMolecular Partners AG25.40x -- $787.5K -$19M
-
Which has Higher Returns ADXN or NLSP?
NLS Pharmaceutics has a net margin of -2841.85% compared to Addex Therapeutics's net margin of --. Addex Therapeutics's return on equity of 91.08% beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics-- -$2.78 $13.1M NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About ADXN or NLSP?
Addex Therapeutics has a consensus price target of $30.00, signalling upside risk potential of 310.4%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12021.21%. Given that NLS Pharmaceutics has higher upside potential than Addex Therapeutics, analysts believe NLS Pharmaceutics is more attractive than Addex Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics0 0 0 NLSPNLS Pharmaceutics0 0 0 -
Is ADXN or NLSP More Risky?
Addex Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADXN or NLSP?
Addex Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or NLSP?
Addex Therapeutics quarterly revenues are $62.3K, which are larger than NLS Pharmaceutics quarterly revenues of --. Addex Therapeutics's net income of -$1.8M is higher than NLS Pharmaceutics's net income of --. Notably, Addex Therapeutics's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics is 13.51x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics13.51x -- $62.3K -$1.8M NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is AST SpaceMobile Stock Dropping?
Since Donald Trump’s pledge to send American astronauts to Mars…
1 Space Stock Up Over 150%, More To Go?
Planet Labs combines satellite imaging and data analytics technologies to…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 104x
Alerts
Buy
69
TECX alert for Jan 31
Tectonic Therapeutic [TECX] is up 0.6% over the past day.
Buy
62
EXOD alert for Jan 31
Exodus Movement [EXOD] is down 9.4% over the past day.
Buy
62
DOGZ alert for Jan 31
Dogness (International) [DOGZ] is up 15.02% over the past day.
